MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574921 | Name: TS-011
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TS-011 is a 20-Hydroxyeicosatetraenoic acid synthesis inhibitor.

Chemical Structure

TS-011
TS-011
CAS#339071-18-0

Theoretical Analysis

MedKoo Cat#: 574921

Name: TS-011

CAS#: 339071-18-0

Chemical Formula: C11H14ClN3O2

Exact Mass: 255.0775

Molecular Weight: 255.70

Elemental Analysis: C, 51.67; H, 5.52; Cl, 13.86; N, 16.43; O, 12.51

Price and Availability

Size Price Availability Quantity
100mg USD 255.00 2 Weeks
250mg USD 415.00 2 Weeks
1g USD 760.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
TS-011; TS011; TS 011
IUPAC/Chemical Name
N-(3-Chloro-4-morpholinophenyl)-N'-hydroxyformimidamide
InChi Key
ZTXADXBIGLLOFX-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H14ClN3O2/c12-10-7-9(13-8-14-16)1-2-11(10)15-3-5-17-6-4-15/h1-2,7-8,16H,3-6H2,(H,13,14)
SMILES Code
O/N=C/NC1=CC=C(N2CCOCC2)C(Cl)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 255.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhou Y, Yu J, Liu J, Cao R, Su W, Li S, Ye S, Zhu C, Zhang X, Xu H, Chen H, Zhang X, Guan Y. Induction of cytochrome P450 4A14 contributes to angiotensin II-induced renal fibrosis in mice. Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):860-870. doi: 10.1016/j.bbadis.2017.12.028. Epub 2017 Dec 19. PMID: 29277328. 2: Marumo T, Eto K, Wake H, Omura T, Nabekura J. The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br J Pharmacol. 2010 Nov;161(6):1391-402. doi: 10.1111/j.1476-5381.2010.00973.x. PMID: 20735406; PMCID: PMC3000662. 3: Renic M, Klaus JA, Omura T, Kawashima N, Onishi M, Miyata N, Koehler RC, Harder DR, Roman RJ. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2009 Mar;29(3):629-39. doi: 10.1038/jcbfm.2008.156. Epub 2008 Dec 24. PMID: 19107134; PMCID: PMC2821901. 4: Tanaka Y, Omura T, Fukasawa M, Horiuchi N, Miyata N, Minagawa T, Yoshida S, Nakaike S. Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res. 2007 Dec;59(4):475-80. doi: 10.1016/j.neures.2007.08.018. Epub 2007 Sep 6. PMID: 17933409. 5: Hacein-Bey L, Harder DR, Meier HT, Varelas PN, Miyata N, Lauer KK, Cusick JF, Roman RJ. Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2006 Jun- Jul;27(6):1350-4. PMID: 16775295; PMCID: PMC8133904. 6: Omura T, Tanaka Y, Miyata N, Koizumi C, Sakurai T, Fukasawa M, Hachiuma K, Minagawa T, Susumu T, Yoshida S, Nakaike S, Okuyama S, Harder DR, Roman RJ. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke. 2006 May;37(5):1307-13. doi: 10.1161/01.STR.0000217398.37075.07. Epub 2006 Apr 6. PMID: 16601220. 7: Roman RJ, Hoagland KM, Lopez B, Kwitek AE, Garrett MR, Rapp JP, Lazar J, Jacob HJ, Sarkis A. Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1463-71. doi: 10.1152/ajprenal.00360.2005. Epub 2006 Jan 5. PMID: 16396943. 8: Takeuchi K, Miyata N, Renic M, Harder DR, Roman RJ. Hemoglobin, NO, and 20-HETE interactions in mediating cerebral vasoconstriction following SAH. Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R84-9. doi: 10.1152/ajpregu.00445.2005. Epub 2005 Sep 15. PMID: 16166205. 9: Takeuchi K, Renic M, Bohman QC, Harder DR, Miyata N, Roman RJ. Reversal of delayed vasospasm by an inhibitor of the synthesis of 20-HETE. Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2203-11. doi: 10.1152/ajpheart.00556.2005. Epub 2005 Jun 17. PMID: 15964920. 10: Miyata N, Seki T, Tanaka Y, Omura T, Taniguchi K, Doi M, Bandou K, Kametani S, Sato M, Okuyama S, Cambj-Sapunar L, Harder DR, Roman RJ. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther. 2005 Jul;314(1):77-85. doi: 10.1124/jpet.105.083964. Epub 2005 Apr 14. PMID: 15831442.

View History

Dryofragin

Dryofragin